tiprankstipranks
United Laboratories Advances Dry Eye Treatment Trial
Company Announcements

United Laboratories Advances Dry Eye Treatment Trial

The United Laboratories International Holdings (HK:3933) has released an update.

Don't Miss Our Christmas Offers:

The United Laboratories International Holdings Limited has successfully enrolled the first subject in their Phase IIa clinical trial in China for TUL12101 Eye Drops, aiming to treat dry eye syndrome. This follows positive Phase I trial results, indicating good safety and tolerability of the drops. The company, a pioneer in developing RASP inhibitors in China, is looking to strengthen its position in the ophthalmic drug market.

For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskUnited Laboratories Gains Approval for Mupirocin Ointment
TipRanks HongKong Auto-Generated NewsdeskThe United Laboratories Vests Over 3 Million Shares
TipRanks HongKong Auto-Generated NewsdeskUnited Laboratories’ Antibiotic Gains Key Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App